Hossam El Benawi Shares Multi Site LVT Study from Mayo Clinic
Hossam El Benawi, Senior Clinical Research Fellow of Cardiovascular Medicine at Mayo Clinic, shared on LinkedIn:
”Mayo Clinic Multi Site LVT Study Part 1:
DOAC Vs VKA for LVT.”
A Mayo Clinic multi-site study of 182 patients with left ventricular thrombus (LVT) found that direct oral anticoagulants (DOACs) and vitamin K antagonists (VKAs) had similar effectiveness in preventing stroke or embolism and achieving thrombus resolution.
However, VKAs were linked to a higher risk of major bleeding.
The risk of embolization was greatest within the first eight weeks, suggesting that an initial DOAC loading dose may help reduce early events.
Read the full article in RPTH/ScienceDirect.
Article: Comparison of direct oral anticoagulants and vitamin K antagonists in the treatment of left ventricular thrombi: a retrospective cohort study
Authors: Hossam El Benawi, Kirsten Lipps, Samuel Heller Jr., David A. Liedl, Raymond C. Shields, Ana I. Casanegra, Stanislav Henkin, Thom W. Rooke, Paul W. Wennberg, Waldemar E. Wysokinski, Robert D. McBane, Damon E. Houghton
Stay updated on all scientific advances in the field of thrombosis with Hemostasis Today.
-
Oct 27, 2025, 12:12Maria Roussakis: It is an Honour to Be a Part of the ISBT Young Professionals Council
-
Oct 27, 2025, 05:47Ahmed Koriesh on The Novel Approach in Use of Tenecteplase
-
Oct 27, 2025, 04:42Louise Breslin: Exciting Results in The CRYPTICS Trial
-
Oct 26, 2025, 16:55ECTH 2025: 3 Unforgettable Days of Science and Shared Purpose
-
Oct 26, 2025, 16:35Ahmed Koriesh on Thrombolysis in Stroke Patients on DOACs
-
Oct 27, 2025, 13:00Hossam El Benawi Shares Multi Site LVT Study from Mayo Clinic
-
Oct 27, 2025, 08:01Acquired Hemophilia A (AHA) is Rare and Often Missed - RPTH Journal
-
Oct 27, 2025, 05:00Wolfgang Miesbach on WFH Guidelines Covering FDA/EMA-Approved AAV Gene Therapy for Hemophilia
-
Oct 26, 2025, 15:04Nita Radhakrishnan and Colleagues on Inherited Haematological Conditions
-
Oct 26, 2025, 14:55Anirban Sen Gupta on Biosynthetic Blood Surrogates Current State-of-Art
-
Oct 25, 2025, 07:42Adithya Hande: India’s Silent Killer and a Scientific Breakthrough
-
Oct 23, 2025, 09:57Arun V. J: Artificial Blood Is Closer Than You Think
-
Oct 23, 2025, 07:11Sebastien Lobet Presented the ACTIVLIM-Hemo Scale
-
Oct 23, 2025, 07:05Syed Ehsan Shah on Advantages of Werfen HemoCell Automation
-
Oct 22, 2025, 08:25Johanna Nystedt: Not Every Day We Can Release a New Blood Product to Meet An Unmet Medical Need!
-
Oct 27, 2025, 13:18Stroke Foundation Welcomes Jacqui McCallum as the New Executive Director
-
Oct 27, 2025, 12:54Guillermo Lahera Forteza on Stroke and Mental Health
-
Oct 27, 2025, 12:37Joshua Ngimbwa Recognised as the Best Male Junior Investigator Awardee at the Tanzania Health Summit
-
Oct 27, 2025, 08:00Rohit Gosain: Revumenib is Now FDA Approved for R/R AML with NPM1 Mutation
-
Oct 27, 2025, 06:30Andres Ricaurte Fajardo on CVT Experience from a Latin American Cohort